Your browser doesn't support javascript.
loading
Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population.
Estrada, Karol; Aukrust, Ingvild; Bjørkhaug, Lise; Burtt, Noël P; Mercader, Josep M; García-Ortiz, Humberto; Huerta-Chagoya, Alicia; Moreno-Macías, Hortensia; Walford, Geoffrey; Flannick, Jason; Williams, Amy L; Gómez-Vázquez, María J; Fernandez-Lopez, Juan C; Martínez-Hernández, Angélica; Jiménez-Morales, Silvia; Centeno-Cruz, Federico; Mendoza-Caamal, Elvia; Revilla-Monsalve, Cristina; Islas-Andrade, Sergio; Córdova, Emilio J; Soberón, Xavier; González-Villalpando, María E; Henderson, E; Wilkens, Lynne R; Le Marchand, Loic; Arellano-Campos, Olimpia; Ordóñez-Sánchez, Maria L; Rodríguez-Torres, Maribel; Rodríguez-Guillén, Rosario; Riba, Laura; Najmi, Laeya A; Jacobs, Suzanne B R; Fennell, Timothy; Gabriel, Stacey; Fontanillas, Pierre; Hanis, Craig L; Lehman, Donna M; Jenkinson, Christopher P; Abboud, Hanna E; Bell, Graeme I; Cortes, Maria L; Boehnke, Michael; González-Villalpando, Clicerio; Orozco, Lorena; Haiman, Christopher A; Tusié-Luna, Teresa; Aguilar-Salinas, Carlos A; Altshuler, David; Njølstad, Pål R; Florez, Jose C.
Afiliación
  • Estrada K; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts2Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston3Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Aukrust I; KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway6Department of Biomedicine, University of Bergen, Bergen, Norway.
  • Bjørkhaug L; KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway5Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
  • Burtt NP; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Mercader JM; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts7Center for Human Genetic Research and Diabetes Research Center (Diabetes Unit), Massachusetts General Hospital, Boston8Joint BSC-CRG-IRB Research Prog.
  • García-Ortiz H; Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.
  • Huerta-Chagoya A; Instituto de Investigaciones Biomédicas, UNAM Unidad de Biología Molecular y Medicina Genómica, UNAM/INCMNSZ, Coyoacán, Mexico City, Mexico.
  • Moreno-Macías H; Universidad Autónoma Metropolitana, Tlalpan, Mexico City, Mexico.
  • Walford G; Department of Medicine, Harvard Medical School, Boston, Massachusetts7Center for Human Genetic Research and Diabetes Research Center (Diabetes Unit), Massachusetts General Hospital, Boston.
  • Flannick J; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts13Department of Molecular Biology, Harvard Medical School, Boston, Massachusetts.
  • Williams AL; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts14Department of Biological Sciences, Columbia University, New York, New York.
  • Gómez-Vázquez MJ; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Sección XVI, Tlalpan, Mexico City, Mexico.
  • Fernandez-Lopez JC; Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.
  • Martínez-Hernández A; Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.
  • Jiménez-Morales S; Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.
  • Centeno-Cruz F; Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.
  • Mendoza-Caamal E; Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.
  • Revilla-Monsalve C; Unidad de Investigación Médica en Enfermedades Metabólicas, CMN SXXI, Instituto Mexicano del Seguro Social, Mexico City.
  • Islas-Andrade S; Unidad de Investigación Médica en Enfermedades Metabólicas, CMN SXXI, Instituto Mexicano del Seguro Social, Mexico City.
  • Córdova EJ; Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.
  • Soberón X; Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.
  • González-Villalpando ME; Centro de Estudios en Diabetes, Unidad de Investigacion en Diabetes y Riesgo Cardiovascular, Centro de Investigacion en Salud Poblacional, Instituto Nacional de Salud Publica, Mexico City, Mexico.
  • Henderson E; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
  • Wilkens LR; Epidemiology Program, University of Hawaii Cancer Center, Honolulu.
  • Le Marchand L; Epidemiology Program, University of Hawaii Cancer Center, Honolulu.
  • Arellano-Campos O; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Sección XVI, Tlalpan, Mexico City, Mexico.
  • Ordóñez-Sánchez ML; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Sección XVI, Tlalpan, Mexico City, Mexico.
  • Rodríguez-Torres M; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Sección XVI, Tlalpan, Mexico City, Mexico.
  • Rodríguez-Guillén R; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Sección XVI, Tlalpan, Mexico City, Mexico.
  • Riba L; Instituto de Investigaciones Biomédicas, UNAM Unidad de Biología Molecular y Medicina Genómica, UNAM/INCMNSZ, Coyoacán, Mexico City, Mexico.
  • Najmi LA; KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway23Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway.
  • Jacobs SB; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Fennell T; The Genomics Platform, The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Gabriel S; The Genomics Platform, The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Fontanillas P; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Hanis CL; Human Genetics Center, University of Texas Health Science Center at Houston.
  • Lehman DM; Department of Medicine, University of Texas Health Science Center at San Antonio.
  • Jenkinson CP; Department of Medicine, University of Texas Health Science Center at San Antonio.
  • Abboud HE; Department of Medicine, University of Texas Health Science Center at San Antonio.
  • Bell GI; Department of Human Genetics, University of Chicago, Chicago, Illinois28Department of Medicine, University of Chicago, Chicago, Illinois.
  • Cortes ML; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Boehnke M; Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor.
  • González-Villalpando C; Centro de Estudios en Diabetes, Unidad de Investigacion en Diabetes y Riesgo Cardiovascular, Centro de Investigacion en Salud Poblacional, Instituto Nacional de Salud Publica, Mexico City, Mexico.
  • Orozco L; Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.
  • Haiman CA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
  • Tusié-Luna T; Instituto de Investigaciones Biomédicas, UNAM Unidad de Biología Molecular y Medicina Genómica, UNAM/INCMNSZ, Coyoacán, Mexico City, Mexico17Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Sección XVI, Tlalpan, Mexico City, Mexico.
  • Aguilar-Salinas CA; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Sección XVI, Tlalpan, Mexico City, Mexico.
  • Altshuler D; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts3Department of Medicine, Harvard Medical School, Boston, Massachusetts7Center for Human Genetic Research and Diabetes Research Center (Diabetes Unit).
  • Njølstad PR; KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway5Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
  • Florez JC; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts3Department of Medicine, Harvard Medical School, Boston, Massachusetts7Center for Human Genetic Research and Diabetes Research Center (Diabetes Unit).
JAMA ; 311(22): 2305-14, 2014 Jun 11.
Article en En | MEDLINE | ID: mdl-24915262
ABSTRACT
IMPORTANCE Latino populations have one of the highest prevalences of type 2 diabetes worldwide.

OBJECTIVES:

To investigate the association between rare protein-coding genetic variants and prevalence of type 2 diabetes in a large Latino population and to explore potential molecular and physiological mechanisms for the observed relationships. DESIGN, SETTING, AND

PARTICIPANTS:

Whole-exome sequencing was performed on DNA samples from 3756 Mexican and US Latino individuals (1794 with type 2 diabetes and 1962 without diabetes) recruited from 1993 to 2013. One variant was further tested for allele frequency and association with type 2 diabetes in large multiethnic data sets of 14,276 participants and characterized in experimental assays. MAIN OUTCOME AND

MEASURES:

Prevalence of type 2 diabetes. Secondary outcomes included age of onset, body mass index, and effect on protein function.

RESULTS:

A single rare missense variant (c.1522G>A [p.E508K]) was associated with type 2 diabetes prevalence (odds ratio [OR], 5.48; 95% CI, 2.83-10.61; P = 4.4 × 10(-7)) in hepatocyte nuclear factor 1-α (HNF1A), the gene responsible for maturity onset diabetes of the young type 3 (MODY3). This variant was observed in 0.36% of participants without type 2 diabetes and 2.1% of participants with it. In multiethnic replication data sets, the p.E508K variant was seen only in Latino patients (n = 1443 with type 2 diabetes and 1673 without it) and was associated with type 2 diabetes (OR, 4.16; 95% CI, 1.75-9.92; P = .0013). In experimental assays, HNF-1A protein encoding the p.E508K mutant demonstrated reduced transactivation activity of its target promoter compared with a wild-type protein. In our data, carriers and noncarriers of the p.E508K mutation with type 2 diabetes had no significant differences in compared clinical characteristics, including age at onset. The mean (SD) age for carriers was 45.3 years (11.2) vs 47.5 years (11.5) for noncarriers (P = .49) and the mean (SD) BMI for carriers was 28.2 (5.5) vs 29.3 (5.3) for noncarriers (P = .19). CONCLUSIONS AND RELEVANCE Using whole-exome sequencing, we identified a single low-frequency variant in the MODY3-causing gene HNF1A that is associated with type 2 diabetes in Latino populations and may affect protein function. This finding may have implications for screening and therapeutic modification in this population, but additional studies are required.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Factor Nuclear 1-alfa del Hepatocito Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Mexico Idioma: En Revista: JAMA Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Factor Nuclear 1-alfa del Hepatocito Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Mexico Idioma: En Revista: JAMA Año: 2014 Tipo del documento: Article